CS238634B2 - Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane - Google Patents

Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane Download PDF

Info

Publication number
CS238634B2
CS238634B2 CS827837A CS783782A CS238634B2 CS 238634 B2 CS238634 B2 CS 238634B2 CS 827837 A CS827837 A CS 827837A CS 783782 A CS783782 A CS 783782A CS 238634 B2 CS238634 B2 CS 238634B2
Authority
CS
Czechoslovakia
Prior art keywords
cyano
methylase
calculated
analysis
methoxyphenyl
Prior art date
Application number
CS827837A
Other languages
Czech (cs)
English (en)
Inventor
Oskar Ehrmann
Manfred Raschack
Josef Gries
Rolf Kretzschmar
Hans D Lehmann
Ludwig Friedrich
Frank Zimmermann
Werner Seitz
Hans J Treiber
Ferdinand Dengel
Wolfram Frank
Hans-Georg Kurbjuweit
Claus D Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CS238634B2 publication Critical patent/CS238634B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CS827837A 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane CS238634B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3114497 1981-04-10
DE19813144150 DE3144150A1 (de) 1981-04-10 1981-11-06 (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
CS238634B2 true CS238634B2 (en) 1985-12-16

Family

ID=25792602

Family Applications (4)

Application Number Title Priority Date Filing Date
CS827837A CS238634B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
CS827838A CS238635B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
CS822458A CS238621B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1,omega-diphenylazaalcane
CS827839A CS238636B2 (en) 1981-04-10 1982-04-06 Production method of derivatives of omega-cyan-1,omega-diphenylazaalkane

Family Applications After (3)

Application Number Title Priority Date Filing Date
CS827838A CS238635B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
CS822458A CS238621B2 (en) 1981-04-10 1982-04-06 Production method of new derivatives of omega-cyan-1,omega-diphenylazaalcane
CS827839A CS238636B2 (en) 1981-04-10 1982-04-06 Production method of derivatives of omega-cyan-1,omega-diphenylazaalkane

Country Status (19)

Country Link
US (1) US4438131A (da)
EP (1) EP0064158B1 (da)
AU (1) AU546383B2 (da)
CA (1) CA1184186A (da)
CS (4) CS238634B2 (da)
DD (1) DD201778A5 (da)
DE (2) DE3144150A1 (da)
DK (1) DK156513C (da)
ES (4) ES511260A0 (da)
FI (1) FI76550C (da)
GB (1) GB2100252B (da)
GR (1) GR75531B (da)
HU (1) HU186058B (da)
IE (1) IE54044B1 (da)
MX (1) MX9203501A (da)
NO (1) NO152129C (da)
PH (1) PH19739A (da)
SG (1) SG78584G (da)
SU (1) SU1308195A3 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3344755A1 (de) * 1983-12-10 1985-06-20 Basf Ag, 6700 Ludwigshafen 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
US4612329A (en) * 1984-10-17 1986-09-16 Hokuriku Pharmaceutical Co., Ltd. Pharmaceutical alpha-aminoalkyl-alpha-alkylphenylacetonitriles
US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
FR2588258B1 (fr) * 1985-10-04 1989-12-15 Adir Nouveaux derives d'amino-5 valeronitrile, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
DE3535949A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
DE3535950A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
DE3665059D1 (en) * 1985-10-18 1989-09-21 Searle & Co Bicyclo-substituted phenylacetonitrile derivatives
US4593042A (en) * 1985-10-18 1986-06-03 G. D. Searle & Co. Bicyclo-substituted phenylacetonitrile derivatives
DE3542994A1 (de) * 1985-12-05 1987-06-11 Basf Ag Basisch substituierte phenylacetaldehyde, ihre herstellung und diese enthaltende arzneimittel
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
CS258534B1 (en) * 1986-07-18 1988-08-16 Ludvik Blaha Derivatives of valeronitrile and method of their preparation
DE3634389A1 (de) * 1986-10-09 1988-04-21 Knoll Ag Verwendung von anipamil
DE3642331A1 (de) * 1986-12-11 1988-06-23 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
ES2011011B3 (es) * 1986-12-13 1989-12-16 Basf Ag Preparado de combinacion
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
CS164891A3 (en) * 1991-05-31 1992-12-16 Vyzk Ustav Farm Biochem Sp N-arylalkyl derivatives of 2-aminomethyl-1,4-benzodioxan, and process forpreparing thereof
DE4124252A1 (de) * 1991-07-22 1993-01-28 Knoll Ag Verfahren zur herstellung einer sterilfiltrierbaren wirkstoffloesung
DE4234000A1 (de) * 1992-10-09 1994-04-14 Knoll Ag Verfahren zur Racemattrennung von Anipamil
SI2170050T1 (sl) * 2007-06-20 2014-12-31 Milestone Pharmaceuticals Inc. Fenilalkilaminski blokatorji kalcijevih kanalov s kratkotrajnim delovanjem in njihova uporaba
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
US9504747B2 (en) 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA916719A (en) 1972-12-12 Dengel Ferdinand Basically substituted phenylacetonitriles and method for their preparation
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE1643429A1 (de) * 1967-09-20 1971-01-28 Knoll Ag Basisch substituierte Phenylacetonitrile und Verfahren zu deren Herstellung
GB1202500A (en) 1967-12-08 1970-08-19 Knoll Ag Substituted phenylacetonitriles
GB1202750A (en) 1967-12-11 1970-08-19 Knoll Ag Substituted phenylacetonitriles
DE2059985C3 (de) 1970-12-05 1979-10-04 Knoll Ag, 6700 Ludwigshafen Rechtsdrehende, basisch substituierte Phenylacetonitrile, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2059923C3 (de) 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
DE2946545A1 (de) 1979-11-17 1981-05-27 Basf Ag, 6700 Ludwigshafen Verfahren zur gewinnung der enantiomeren formen von 4-cyan-1-(n-methyl-n-(2'-((3'',4'',-dimethoxyphenyl))-aethyl)-amino)-5-methyl-4-(3',4',5'-trimethoxyphenyl)-hexan und dessen salzen

Also Published As

Publication number Publication date
DK156513C (da) 1990-02-05
FI76550B (fi) 1988-07-29
DK156513B (da) 1989-09-04
ES521545A0 (es) 1984-01-16
SU1308195A3 (ru) 1987-04-30
ES8402261A1 (es) 1984-01-16
IE820856L (en) 1982-10-10
MX9203501A (es) 1992-09-01
IE54044B1 (en) 1989-05-24
ES8307210A1 (es) 1983-07-01
GR75531B (da) 1984-07-26
GB2100252A (en) 1982-12-22
FI821252A0 (fi) 1982-04-07
PH19739A (en) 1986-06-23
ES511260A0 (es) 1983-07-01
NO152129B (no) 1985-04-29
DE3262516D1 (en) 1985-04-18
NO821085L (no) 1982-10-11
CS238635B2 (en) 1985-12-16
EP0064158A1 (de) 1982-11-10
CS238636B2 (en) 1985-12-16
DE3144150A1 (de) 1982-12-09
FI821252L (fi) 1982-10-11
AU546383B2 (en) 1985-08-29
GB2100252B (en) 1984-06-27
ES521543A0 (es) 1984-02-01
HU186058B (en) 1985-05-28
FI76550C (fi) 1988-11-10
NO152129C (no) 1985-08-07
AU8249082A (en) 1983-04-21
ES8402560A1 (es) 1984-02-01
CA1184186A (en) 1985-03-19
US4438131A (en) 1984-03-20
CS238621B2 (en) 1985-12-16
DK159882A (da) 1982-10-11
SG78584G (en) 1985-04-26
EP0064158B1 (de) 1985-03-13
DD201778A5 (de) 1983-08-10
ES521544A0 (es) 1984-01-16
ES8402262A1 (es) 1984-01-16

Similar Documents

Publication Publication Date Title
CS238634B2 (en) Production method of new derivatives of omega-cyan-1-omega-diphenylazaalkane
KR910000864B1 (ko) 신규의 의약품
BG60428B2 (bg) Бензимидазоли,метод за получаването им и лекарствени средства, които ги съдържат
GB2132609A (en) Intermediates for hypoglycemic 5-substituted oxazolidine-2,4-diones
US3987200A (en) Method for increasing cardiac contractility
WO1996039133A1 (en) Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
IE49462B1 (en) New fluorine-containing 1,4-dihydropyridine compounds,their production and their medicinal use
DK142750B (da) Analogifremgangsmaade til fremstilling af racemiske eller optisk aktive dopaminderivater eller syreadditionssalte deraf
EP0350878B1 (en) Conjugated gamma-oxybutenolide compounds for treating ulcer
HU193523B (en) Process for preparing 2-/2'-hydroxy-3'-/1,1-dimethyl-propyl-amino /-propoxy/-beta-phenyl-propiophenone
EP0543713B1 (fr) Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
US4968717A (en) Phenylacetonitriles which are substituted by basic groups, their preparation and drugs containing these substances
CA1268471A (en) Phenylacetaldehydes substituted by basic groups, their preparation and drugs containing these compounds
JPS6334865B2 (da)
US4755520A (en) Spartein compounds, their preparation and use
JPH0443064B2 (da)
JP3660395B2 (ja) フェニルスルホン誘導体及びその製造方法
Franke et al. 2-(Isoxazolylethenyl) phenoxypropanolamines: a new class of. beta.-receptor antagonists with antihypertensive activity
JPS58501124A (ja) フエニルアルキルオキシランカルボン酸、その製法、その使用及びそれを含有する医薬品
JPH0419224B2 (da)
SU1470178A3 (ru) Способ получени производных @ -циано-1, @ -дифенилазаалканов или их кислотно-аддитивных солей
JPS597714B2 (ja) 新規な２−アミノ−４ｈ−ピラン化合物の製造法
SU1213984A3 (ru) Способ получени производных @ -циано-1, @ -дифенилазаалканов (его варианты)
US3961076A (en) α-Aminoalkyl-4-hydroxy-3-alkylsulfonylmethylbenzyl alcohols having β-adrenergic stimulant activity
HU204502B (en) Process for producing aminopropanol derivatives of 3-(3-hydroxy-phenyl)-1-propanones and pharmaceutical compositions containing them